Physician profile

Irwin M Lieb

Urology · Saranac Lake, NY

NPI 1447242920

$1,375.86

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$104.02

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astellas Pharma US INC $341.24 2019-2020
Janssen Biotech, INC. $329.53 2019-2020
Pfizer INC. $209.64 2019-2020
Abbvie INC. $172.12 2019-2020
Allergan, INC. $104.33 2019
Boston Scientific Corporation $104.02 2023 Rezum Generator
Coloplast Corp $39.12 2019
Dendreon Pharmaceuticals LLC $30.88 2019
180 Medical, INC. $19.71 2020
Bayer Healthcare Pharmaceuticals INC. $14.36 2019
Hollister Incorporated $10.91 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Irwin M Lieb

$1,375.86

in general payments reported 2019-2025

Years
2019-2023
Top company
Astellas Pharma US INC

https://glasscript.com/doctor/292461/irwin-m-lieb

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.